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objectives. Adult patients with type 2 diabetes mellitus (T2DM) newly initiating 
treatment between January 1, 2010, and December 31, 2011, with either saxagliptin 
or sitagliptin were identified. A 1:1 propensity-matched sample of saxagliptin and 
sitagliptin patients was created to reduce any potential confounding. Propensity 
scores were generated based on demographic characteristics, comorbidities, disease 
severity and treatment patterns before the index date. Patients were required to 
have ≥ 6 months of continuous eligibility before (baseline period) and after (follow-
up period) treatment initiation. All outcomes were assessed based on an intent-to-
treat analysis in the 6-month follow-up period. Both overall and diabetes-specific 
charges were computed; breakdowns of medical and overall (medical plus phar-
macy) charges were compared. Appropriate univariate statistical tests were applied 
to the propensity-matched sample to examine differences in resource utilization 
outcomes. Results: A total of 8,438 and 23,155 patients initiated treatment with 
saxagliptin and sitagliptin, respectively. After matching, each cohort consisted of 
7,700 patients. Compared with sitagliptin, during the follow-up period, saxagliptin 
was associated with significantly lower (all p values ≤ 0.01) overall charges ($13,203 
± $28,391 vs. $14,258 ± $35,586), diabetes-related overall charges ($5,106 ± $12,129 vs. 
$5,402 ± $14,201), overall medical charges ($9,454 ± $27,616 vs. $10,502 ± $34,903), and 
diabetes-related medical charges ($3,389 ± $12,080 vs. $3,689 ± $14,161). Accordingly, 
saxagliptin was associated with a lower proportion of patients recording an inpa-
tient stay (6.6% vs. 8.1%; p= 0.001) or diabetes-related inpatient stay (4.6% vs. 5.4%; 
p= 0.025). ConClusions: Patients initiating saxagliptin treatment reported lower 
charges and lower hospitalization rates (overall and diabetes-related) compared 
with patients initiating sitagliptin.
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objeCtives: Wearable health monitoring devices have become increasingly avail-
able and allow for real-time tracking of clinical values. This research aims to assess 
the trends in continuous glucose monitor (CGM) uptake and to examine differences 
in costs and resource utilization following their initial use. Methods: Adults aged 
18-64 with a diagnosis for diabetes (ICD-9-CM 250.xx) and continuous enrollment 
in commercial insurance were identified from the Truven Health MarketScan 
databases (2008-2012). An initial procedure code for CGM (CPT 95250) at least one 
year after the initial diagnosis and the lack of a previous claim for CGM identi-
fied eligible subjects within each year from 2009-2011; the date of the qualifying 
CGM claim served as the index date. Costs and utilization for pharmacy, inpatient, 
emergency department, specialty, laboratory, and primary care services were com-
pared between each annual cohort and between the year prior to and following the 
index date. Results: From 2009 to 2011, the number of initial patients using CGM 
declined, from 1,001 to 770 (p-value for trend < 0.001). The total average costs to treat 
these patients increased between 2009 and 2010 before declining in 2011, mostly due 
to dramatic changes in costs related to outpatient pharmacy and inpatient services. 
Compared to before the CGM was placed, mean annual costs for primary care visits 
and laboratory services tended to decrease while the average number of primary 
care visits consistently and significantly declined (all p< 0.05). However, noticeably 
higher mean costs related to outpatient pharmacy services were accrued following 
CGM use in both 2009 and 2010. ConClusions: Devices such as CGM may benefit 
ongoing patient care by providing more regular insight to treatment progression 
and, in some cases, lead to more efficient care.
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objeCtives: As novel treatments for type II diabetes enter the market, there is a 
need to assess their long-term clinical and economic outcomes compared to cur-
rent treatments. These comparisons can assist decision-makers in determining 
the appropriate place in therapy. Our objective was to review the existing phar-
macoeconomic literature evaluating the cost-effectiveness and overall costs of 
treatment associated with liraglutide in type II diabetes. Methods: We identified 
English-language cost-effectiveness, cost-utility or cost analyses that compared 
liraglutide to one or more anti-diabetic agents via MEDLINE and EMBASE through 
March 1, 2013. Full text articles meeting the inclusion criteria were retrieved and 
information on the study design and results were abstracted. Costs were converted 
to 2012 US dollars in order to facilitate comparisons across studies. Results: A 
total of 3 cost comparison studies and 6 cost-utility studies were identified for 
inclusion. Across cost comparison studies, liraglutide treatment resulted in cost 
savings ranging from $1,075 to $1,298 (1.2 mg) and $1,162 to $2,147 (1.8 mg) over a 
10 year time horizon. Cost-utility analysis results reported base case ICERs ranging 
from $15,774 to $40,128/QALY for liraglutide 1.2 mg and $8,497 to $66,031/QALY 
for liraglutide 1.8 mg. Estimates were most sensitive to variations in time horizon 
and cardiovascular complication rates. Based on often cited cost-utility thresholds, 
liraglutide was determined to have a probability of being cost effective between 58% 
(liraglutide 1.8 mg vs. sitagliptin 100 mg) and 93% (liraglutide 1.2 mg vs. glimepiride 
4 mg). ConClusions: Liraglutide appears to be a cost-effective adjunct treatment 
for type II diabetes and may also be associated with a reduction in diabetes-related 
complication costs; however, ICER values are largely dependent on the duration of 
liraglutide treatment benefit and the time horizon of the analysis.
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performed to assess the association between CKD stages and HRU/costs. Results: 
The study identified 23,492 T2DM patients (mean age: 60.7 years; no CKD: 54.9%; 
stage 1: 7.1%; stage 2: 12.7%; stage 3A: 15.9%; stage 3B: 7.5%; stage 4: 1.8%). Patients 
with more advanced CKD stages were associated with greater odds of hospitaliza-
tion compared to those without CKD (odds ratio [95% confidence interval] (stage 
1: 1.14 [1.00−1.30]; stage 3A: 1.57 [1.43−1.72]; stage 3B: 1.84 [1.63−2.07]; stage 4: 2.66 
[2.16−3.28]) and ER visits (stage 3A: 1.25 [1.15−1.37]; stage 3B: 1.34 [1.19−1.51]; stage 
4: 1.55 [1.25−1.92]). Patients with CKD stage 1, 2, 3A, 3B, and 4 had total costs of 1.18, 
1.17, 1.44, 1.54, and 1.80 times of those without CKD (all p< 0.01). ConClusions: 
CKD in T2DM patients was associated with higher HRU and costs compared to those 
without CKD. Additionally, HRU and costs increased with more advanced stages 
of CKD. Prevention of CKD progression may help contain the economic burden.
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objeCtives: To assess the impact of diabetes on direct medical expenditures 
for visits and prescribed medications related to skin and soft tissue infections 
(SSTIs). Methods: Hospital inpatient, outpatient, office, and emergency room vis-
its and prescribed medications related to SSTIs were identified from the 2010 and 
2011 Medical Expenditure Panel Survey. Total SSTI costs per patient per year were 
calculated by summing overall costs of all SSTI medical events. Differences in mean 
and median SSTI costs between patients with and without diabetes were assessed 
with the Wilcoxon-Mann-Whitney and median two-sample tests. Results: We 
identified 1684 SSTI events from 438 patients, including 93 (21%) having diabetes. 
Events (761 to 923) and costs ($259,784.74 to $375,696.03) increased from 2010 to 2011. 
Patients with diabetes were older (61 vs. 47) and a greater percentage had public 
insurance (46% vs. 28%). Average SSTI costs per patient with diabetes in 2010 and 
2011 were: $135.84 (standard deviation [sd]= 259.72) and $873.59 (sd= 2275.98) for 
prescribed medicines, $8990.54 (sd= 9506.02) and $8590.86 (sd= 8685.70) for inpatient 
and emergency room, $706.61 (sd= 1729.25) and $1255.25 (sd= 3561.37) for outpa-
tient and office. Average SSTI costs per patient without diabetes in 2010 and 2011 
were: $143.91 (standard deviation [sd]= 411.68) and $46.71 (sd= 78.07) for prescribed 
medicines, $832.92 (sd= 1482.56) and $2431.65 (sd= 7758.02) for inpatient and emer-
gency room, $486.55 (sd= 1237.81) and $568.32 (sd= 1247.08) for outpatient and office. 
The mean total SSTI cost difference between patients with and without diabetes 
was $1627.93 ($2481.09-$853.16, p-value= 0.1441) in 2010 and $1065.60 ($2604.75-
$1539.15, p-value= 0.1789) in 2011. The median total SSTI cost difference per patient 
per year was $78.61 ($237.72-$159.11, p-value= 0.3948) and $38.21 ($237.00-$198.79, 
p-value= 0.2666). ConClusions: In a nationally representative sample, mean and 
median SSTI costs related to medical visits and prescriptions were higher among 
patients with diabetes, however these costs did not differ significantly compared 
to patients without diabetes.
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objeCtives: Identify, categorize the two year costs (insurer paid amount) of inten-
sive insulin treatment for patients diagnosed with type 2 diabetes. Focus on inten-
sively-treated patients receiving MDI (multiple daily injections of insulin) or CSII 
(continuous subcutaneous insulin infusion). Investigate and measure the spending 
by payers for these patients determine which related diagnosis contribute the most 
to the two year aggregate. Methods: Patients and their expenditures were identi-
fied retrospectively using administrative health care insurance claims from the 
2010 and 2011 edition of Truven MarketScan Commercial. Patients were identified 
as having type 2 diabetes based on diagnosis from these claims. Treatment groups 
were assigned from medical-surgical and drug benefit claims for insulin, an insulin 
pump or related supplies. Patients with a claim for type 1 diabetes, gestational dia-
betes, cancer, HIV/AIDS, trauma, organ transplants were excluded. Patients in the 
lowest or highest 99th cost percentile and patients without continuous enrollment 
for the entire period were excluded. Expenditures were segmented by benefit type 
and were stratified separately as “diabetes-related” if the claim’s primary ICD-9-CM 
code was related to diabetes. Conversely, claims with primary diagnosis codes not 
related to diabetes were classified as “not related to diabetes”. Results: After exclu-
sions, there were 20,355 patients identified as MDI and 481 patients identified as 
using CSII. For both groups, the majority of the total treatment expenditures were 
not related to diabetes. For patients in the same treatment cohort of the prior year 
(ie. 2011 vs. 2010), the proportion of expenditures were similar. ConClusions: 
For patients identified as MDI or CSII, non-diabetes related costs were the highest 
contributors to aggregate payer spending. Further analysis is needed to determine 
if other characteristics of the patients analyzed have an effect on the proportion 
of costs.
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objeCtives: To compare charges and resource use during the 6 months follow-
ing treatment initiation with saxagliptin or sitagliptin. Methods: A retrospective 
cohort study using a US insurance claims dataset was conducted to meet the study 
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cross-sectional survey was conducted among total of 350 diabetic patients randomly 
selected including 175 each from private and public hospitals. The study was con-
ducted from May to July 2012 including patients of having at least a year of illness 
and of 30 to 65 years of age. Results: The mean total cost per visit by a diabetic 
patient to a private hospital was US $14.3 (95% CI: 12.70 -16.92) as compared to US $ 
10.31(95% CI: 9.88- 12.36) for public hospital. Similarly, total direct cost for the treat-
ment and care of patients per month was US$ 58.10 (95% CI: 41.33-62.12) in private 
hospital in comparison to US $ 33.22 (95% CI: 27.32- 36.88) for those attending public 
hospitals. The per capita is just US$ 742. ConClusions: The study concludes that 
there was high economic burden on the patients with diabetes getting care from 
private sector as compared to public hospitals.
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objeCtives: Diabetes Mellitus (DM) is a chronic-degerenative disease in the popula-
tion connected to a high risk of onset of chronic complications and co-morbidities. 
Despite that, very low data are available on the cost associated. The objective of 
this study is to identify the available information about the epidemiology of the 
disease and to estimate the average annual cost incurred by the National Health 
Service (NHS) and by the Society for the treatment of diabetes in Italy. Methods: A 
probabilistic prevalence cost of Illness model was developed in order to calculate an 
aggregate measure of the economic burden associated with the disease in terms of 
direct medical (drug, hospitalization, monitoring and AE) and indirect costs (absen-
teeism and early retirement) . A systematic review of the literature was conducted 
to determine both the epidemiological and economic data. Furthermore, a one-way 
and probabilistic sensitivity analysis with 5,000 Monte Carlo simulations were per-
formed in order to test the robustness of the results and define a CI 95%. Results: 
The model estimated a prevalence of 2.6 million of patients with drug therapies 
in Italy. The total economic burden of diabetic patients in Italy amounted to € 20.3 
billion years (95% IC: € 18.61 - € 22.29 billion). Of these, 54% are associated with 
indirect costs (95% CI € 10.10 - € 11.62 billion) and 46% are attributable only to the 
direct costs (95% IC: € 8.11 - € 11 06 billion). ConClusions: This is a first study in 
Italy that aimed to estimate direct and indirect cost of diabetes with probabilistic 
prevalence approach. As might be expected, the lack of information means that the 
real burden of Diabetes is partly underestimated, especially about indirect costs. 
However, this approach can be very useful for policy makers in order to understand 
the economic aspects in the treatment of diabetes in Italy.
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objeCtives: Painful diabetic peripheral neuropathy (pDPN) results from toxic 
effects of chronically high blood sugar on the peripheral nervous system. Symptoms 
include loss of sensation, discomfort and often severe pain in the feet, legs or hands. 
The study aims to determine and characterize the potential total direct and indirect 
costs associated with pDPN in China. Methods: We created a one year model to 
estimate the burden of illness of pDPN in China. The model utilized a micro-costing 
approach. Direct health care costs were for primary treatment drugs, drugs for 
comorbidities, hospitalization utilization, tests, and outpatient visits. Indirect costs 
were projected due to both presenteeism (decreased productivity) and absenteeism 
(missing work). Prevalence rates and resource utilization frequency was informed by 
both publically available data and a questionnaire administered to local physicians. 
Both direct and indirect costs were informed by publically available data. Costs 
were reported in 2013 USD (1 USD = 6.07 RMB). Results: We estimated that pDPN 
affects 30% of the diabetic population—an estimated 33,930,810 people in China. 
The total economic burden of illness of pDPN was estimated to be $110.5 billion 
per year ($60.8 billion and $49.7 billion from direct and indirect costs, respectively). 
Within direct health care costs were primary treatment drugs ($37.1 billion), drugs 
for comorbidities ($13.9 billion), tests ($7.3 billion), hospitalizations ($1.7 billion), 
and outpatient visits ($713 million). For indirect costs, $42.6 billion was associated 
with presenteeism via decreased productivity, and $7.1 billion was associated with 
absenteeism. The estimated total cost per year, per patient is estimated to be $3,255 
($1,791 and $1,465 from direct and indirect costs respectively). ConClusions: In 
China, the aggregate burden of illness for pDPN is estimated to be over $110.5 bil-
lion annually. New treatments for the disease may reduce its burden on society.
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objeCtives: In diabetes management, self-monitoring of blood glucose (SMBG) and 
self-injection of insulin are necessary interventions to control blood glucose. However 
Chinese patients with type 2 diabetes (T2DM) have to pay almost all expenses for 
SMBG and self-injection from out-of-pocket. This paper is intended to calculate the 
costs of SMBG and self-injection for patients with T2DM in China. Methods: A cross-
sectional survey of patients with T2DM was carried out in one tertiary hospital in 
Tianjin and two community hopsitals in Beijing from October to December, 2011, 
which provided sufficient data for research question of this study. Costs of SMGB 
include glucometers and test strips; while costs of self-injection cover insulin pen 
objeCtives: Diabetes imposes a substantial health and economic burden to patients 
and society. This study analyzed the lifetime health care expenditures and life years 
lost associated with diabetes in the United States. Methods: Data from the National 
Health Interview Survey (NHIS), the NHIS linked Mortality Public-use Files, and the 
Medical Expenditure Panel Survey from 1997 to 2000 were used to estimate age-, race-, 
sex-, and body mass index (BMI)-specific risk of diabetes, mortality, and annual health 
care expenditures for both diabetics and non-diabetics. A Markov model populated by 
the risk estimates was used to compute life expectancy and total lifetime health care 
expenditures by age, race, sex, and BMI for diabetics and non-diabetics. Results: 
Predicted life expectancy was longer for females than males and whites and other 
races than blacks. Predicted life expectancy for diabetics and non-diabetics consist-
ently demonstrated an inverted U-shape for BMI across all subgroups, with highest life 
expectancy being for the overweight. Using U.S. adults aged 50 years as an example, 
we found that the life years lost associated with diabetes for white females with a BMI 
above 40 kg/m2 was 12.3 years. Black females of the same age and degree of obesity 
lost 11.2 life years, followed by white males (7.0 years) and black males (5.4 years). 
Lifetime health care expenditures between individuals with and without diabetes 
with a BMI above 40 kg/m42 varied by race and gender: white females ($48,848), black 
females ($47,787), white males ($31,189), and black males ($26,634). ConClusions: 
Our results show that obesity is associated with large decreases in life expectancy and 
large increases in lifetime health care expenditures. In addition, diabetes decreased 
life expectancy by 2.6 to 23.4 years and increased lifetime health care expenditures by 
$6,048 to $121,247 depending on age, gender, race, and BMI classification.
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objeCtives: Type 1 diabetes (T1D) and the associated comorbidities and complica-
tions create a financial burden for patients, caregivers, and the health care system. 
Understanding drivers of costs among specific patient sub-groups is important for 
targeting support initiatives. Methods: Data from a large Medicare Advantage 
payer were used. Members diagnosed with T1D and 24 months of continuous 
enrollment were included. Baseline demographic, clinical, consumer/behavioral, 
and cost characteristics were analyzed. Quantile regression (QR) was used to model 
the relationship between baseline characteristics and health care costs during the 
follow-up period (12 months) across cost quantiles. QR results were compared to 
traditional ordinary least squares (OLS) regression. Results: The sample included 
877 patients with T1D (mean age 65.2 yrs; 52% female). Common comorbidities 
included cardiovascular disease (46%), nephropathy (43%), and retinopathy (40%). QR 
analysis identified many interesting findings. For example, female gender is asso-
ciated with varying impact on costs across the continuum: lower impact in lower 
quantiles (-$24.61 in the 10th percentile, p< 0.10) but considerably higher impact in 
the top quantiles (-$5,537 in the 95th percentile, p< 0.10); however, no significant 
difference in costs was observed between genders in the OLS model. The presence 
of cardiovascular disease did not have a significant impact on costs in the OLS 
model, but showed a significant increase in costs in the lower quantiles ($429.08 in 
the 10th percentile) and a significant reduction in costs in the higher cost quantiles 
(-$4,737 and -$8,247; 90th and 95th percentiles, respectively). ConClusions: This 
study demonstrates the challenges in analyzing cost data due to variations in fac-
tors impacting health care costs across the cost continuum. Care should be taken 
when developing interventions directing resources at those most likely to benefit, 
as traditional regression analysis may be less useful than methods such as QR that 
provide more robust insights into patient sub-groups based on health care cost.
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objeCtives: The primary objective was to estimate the national burden of illness 
in Canada for diabetic foot ulcer (DFU) for 2011. Secondary objectives included 
estimating the national incidence and prevalence of DFU, and the 3-year aver-
age cost for DFU incident cases. Methods: Analyses were conducted using four 
national databases for the period April 1, 2006 to March 31, 2011, with cases being 
identified by ICD-10 CA codes. Resource utilization and costs, expressed in 2011 
Canadian dollars, were estimated for DFU-related hospitalizations, emergency care 
(ER), same day surgeries, home care, long term care, physician visits and caregiver 
time losses. Results: In Canada in the year 2011, DFU was attributed to 20,149 
hospital admissions (408,585 days), 32,174 ER or clinic visits, 110,924 rehabilitation 
clinic visits, and 26,493 interventions, including 6,036 amputations and 5,796 sur-
gical debridements. This acute institution care represented $455.0M, and with an 
additional $125.4M for home care and $63.1M for long term care, the annual cost 
for DFU-related care was $643.5M, or $25,141 annual cost per prevalent case. In 
2011, the national prevalence of DFU was 25,597 cases (75.1 per 100,000 population), 
consisting of 16,161 men (63.1%) and 9,436 women (36.9%), and an estimated 14,449 
incident cases. For an incident case of DFU, the average 3-year cumulative cost was 
$52,360. ConClusions: The annual burden for DFU cases that have at least one 
admission or ER/clinic visit over a 5-year period is higher than previously reported 
because of wound and vascular related admissions and procedures.
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objeCtives: The objective of the study was to estimate the direct and indirect cost 
of treatment among patients attending private and public hospitals. Methods: A 
